Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding

Ratios

Rapport Therapeutics (RAPP) Preferred Shares Issued (2023 - 2024)

Rapport Therapeutics (RAPP) has 2 years of Preferred Shares Issued data on record, last reported at -$87000.0 in Q2 2024.

On a quarterly basis, Preferred Shares Issued changed N/A to -$87000.0 in Q2 2024 year-over-year; TTM through Dec 2024 was $63.9 million, a N/A change, with the full-year FY2024 number at $63.9 million, changed 0.0% from a year prior.
Preferred Shares Issued reached -$87000.0 in Q2 2024 per RAPP's latest filing, down from $64.0 million in the prior quarter.
Over the last five years, Preferred Shares Issued for RAPP hit a ceiling of $64.0 million in Q1 2024 and a floor of -$21.4 million in Q4 2023.